Manuel Modiano

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.8K citations

Adjuvant Docetaxel for Node-Positive Breast Cancer

Miguel Martín, Tadeusz Pieńkowski, John R. Mackey et al. · New England Journal of Medicine · 2005 · 950 citations · Full text

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Ghassan K. Abou‐Alfa, Richard Létourneau, Graydon Harker et al. · Journal of Clinical Oncology · 2006 · 277 citations · Full text

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

John R. Mackey, Miguel Martín, Tadeusz Pieńkowski et al. · The Lancet Oncology · 2012 · 221 citations

Node-positive Breast Cancer, Breast Oncology, Oncology +7

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Ralph Zinner, Coleman K. Obasaju, David R. Spigel et al. · Journal of Thoracic Oncology · 2014 · 171 citations · Full text